SCHEMBL2353161

SCHEMBL2353161

Cc1cc(-c2ccc3cc(CCc4ccccc4)ccc3c2)ccc1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.58
PDE4A P27815 1/20 0.53
PDE4B Q07343 1/20 0.53
PDE4C Q08493 1/20 0.53
PDE4D Q08499 1/20 0.53
RXRB P28702 2/20 0.47
PLAU P00749 1/20 0.47
MCL1 Q07820 2/20 0.46
ADRB1 P08588 1/20 0.46
ADRB3 P13945 1/20 0.46
RXRA P19793 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
ACMSD Q8TDX5 1/20 0.46
FFAR4 Q5NUL3 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FFAR1 O14842 1/20 0.43
ACLY P53396 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2355298 0.92 RARB (0.54) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL14312369 0.85 RARB (0.54) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL2357478 0.82 PLAU (0.55) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL12243162 0.80 MAPT (0.54) PLAUFFAR4SMN1; SMN2CYP1A2
SCHEMBL2362674 0.80 PTGES (0.56) RARBRXRBPLAURXRAFFAR4
SCHEMBL6259744 0.80 RARB (0.49) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL2354635 0.78 PLAU (0.53) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL12243167 0.77 MAPT (0.59) PLAUFFAR4SMN1; SMN2FFAR1CYP1A2
SCHEMBL2367978 0.77 RARB (0.86) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL2353162 0.77 EGFR (0.53) PLAUNPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2010062264-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE MERLION PHARMACEUTICALS PTE LTD (SG) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 RARB 2792/4885PDE4A 1935/4885PDE4B 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.